Cases & Deals

Share

Onxeo completes €40.7 million rights issue

December 2014

Client(s) Onxeo SA

Jones Day represented Onxeo SA, an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, in connection with its €40.7 million (US$50.6 million) issuance of Ordinary Shares. Natixis and Oddo & Cie acted as joint lead managers and joint bookrunners. This was the first simultaneous public offering in France and Denmark.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.